James P. Nataro

James P. Nataro

Auto-generated profile, based on publicly available information

James P. Nataro

Department of Pediatrics, University of Virginia School of Medicine, Box, Charlottesville, VA, United States of America

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2016 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
KBKelly K Baker
Kelly K Baker
COCiara E. O’reilly
Ciara E. O’reilly
MLMyron M. Levine
Myron M. Levine
KKKaren L. Kotloff
Karen L. Kotloff
JNJames P. Nataro
James P. Nataro
EMEric D. Mintz
Eric D. Mintz
Diarrheal disease is the second leading cause of disease in children less than 5 y of age. Poor water, sanitation, and hygiene conditions are the primary routes of exposure and infection. Sanitation and hygiene interventions are estimated to generate a 36% and 48% reduction in diarrheal risk in young children, respectively. Little is known about whether the number of households sharing a sanitation facility affects a child's risk of diarrhea. The objective of this study was to describe sanitation and hygiene access across the Global Enteric Multicenter Study (GEMS) sites in Africa and South Asia and to assess sanitation and hygiene exposures, including shared sanitation access, as risk factors for moderate-to-severe diarrhea (MSD) in children less than 5 y of age. The GEMS matched case-control study was conducted between December 1, 2007, and March 3, 2011, at seven sites in Basse, The Gambia; Nyanza Province, Kenya; Bamako, Mali; Manhiça, Mozambique; Mirzapur, Bangladesh; Kolkata, India; and Karachi, Pakistan. Data was collected for 8,592 case children aged <5 y old experiencing MSD and for 12,390 asymptomatic age, gender, and neighborhood-matched controls. An MSD case was defined as a child with a diarrheal illness 93%) had access to a sanitation facility, while 70% of households in rural Kenya had access to a facility. Practicing open defecation was a risk factor for MSD in children 93%) at six of the sites had access to a sanitation facility, whereas only 70% of households at the Kenyan site had access to a facility. Compared to having a private household sanitation facility, sharing a facility with three or more households significantly increased the risk of young children developing diarrhea (a significantly increased risk is unlikely to have occurred by chance) at the study sites in Kenya, Mali, Mozambique, and Pakistan. At the sites in Kenya, Mali, and Pakistan, sharing a facility with one or two households also increased MSD risk. Sharing a sanitation facility did not increase MSD risk at the sites in The Gambia, Bangladesh, or India. These findings show that sharing a sanitation facility with one or two other households is associated with an increased risk of MSD in young children. Because this was an observational study, these findings only show an association between the use of shared sanitation facilities and MSD risk; they cannot prove that using shared facilities causes diarrhea. It could be, for example, that households who decide to invest in a private sanitation facility also prioritize safe hygiene practices. The reduced risk of diarrhea in these households might then be the result of everyone washing their hands after using the toilet rather than the result of having a private latrine. Nevertheless, these findings suggest that interventions aimed at increasing access to private household sanitation facilities might reduce the global MSD burden. Moreover, they suggest that shared sanitation facilities should continue to be classified as “unimproved” for the purposes of monitoring global access to sanitation. This list of resources contains links that can be accessed when viewing the PDF on a device or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1002010.

1 August 2017 in EBioMedicine
Verified
Journal Article
Open access
BABeatrice Amadi
Beatrice Amadi
EBEllen Besa
Ellen Besa
KZKanekwa Zyambo
Kanekwa Zyambo
PKPatrick Kaonga
Patrick Kaonga
JLJohn Louis-Auguste
John Louis-Auguste
PKPaul Kelly
Paul Kelly
Intestinal damage in malnutrition constitutes a threat to the survival of many thousands of children globally. We studied children in Lusaka, Zambia, with severe acute malnutrition (SAM) and persistent diarrhea using endoscopy, biopsy and analysis of markers and protective proteins in blood and intestinal secretions. We carried out parallel investigations in apparently healthy adults, and analyzed biomarkers only in apparently healthy children. Villus height and crypt depth did not differ in children with SAM and adult controls, but epithelial surface was reduced in children with SAM (median 445, interquartile range (IQR) 388, 562μm per 100μm muscularis mucosae) compared to adults (578, IQR 465,709; P=0.004). Histological lesions and disruptions of claudin-4 and E-cadherin were most pronounced in children with SAM. Circulating lipopolysaccharide, a marker of bacterial translocation, was higher in malnourished children (251, IQR 110,460EU/ml) than in healthy children (51, IQR 0,111; P=0.0001). Other translocation markers showed similar patterns. Anti-Deamidated Gliadin Peptide IgG concentrations, although within the normal range, were higher in children with SAM (median 2.7U/ml, IQR 1.5-8.6) than in adults (1.6, 1.4-2.1; P=0.005), and were inversely correlated with villus height (ρ=-0.79, n=13, P=0.001). Malnutrition enteropathy is associated with intestinal barrier failure and immune dysregulation.

2 November 2014 in Gut Microbes
Verified
Journal Article
Open access
JOJohn B Ochieng
John B Ochieng
NBNadia Boisen
Nadia Boisen
BLBrianna Lindsay
Brianna Lindsay
ASAraceli Santiago
Araceli Santiago
COCollins Ouma
Collins Ouma
JNJames P Nataro
James P Nataro
Diarrhea causes substantial morbidity and mortality in children in low-income countries. Although numerous pathogens cause diarrhea, the etiology of many episodes remains unknown. Serratia marcescens is incriminated in hospital-associated infections, and HIV/AIDS associated diarrhea. We have recently found that Serratia spp. may be found more commonly in the stools of patients with diarrhea than in asymptomatic control children. We therefore investigated the possible enteric pathogenicity of S. marcescens in vitro employing a polarized human colonic epithelial cell (T84) monolayer. Infected monolayers were assayed for bacterial invasion, transepithelial electrical resistance (TEER), cytotoxicity, interleukin-8 (IL-8) release and morphological changes by scanning electron microscopy. We observed significantly greater epithelial cell invasion by S. marcescens compared to Escherichia coli strain HS (p = 0.0038 respectively). Cell invasion was accompanied by reduction in TEER and secretion of IL-8. Lactate dehydrogenase (LDH) extracellular concentration rapidly increased within a few hours of exposure of the monolayer to S. marcescens. Scanning electron microscopy of S. marcescens-infected monolayers demonstrated destruction of microvilli and vacuolization. Our results suggest that S. marcescens interacts with intestinal epithelial cells in culture and induces dramatic alterations similar to those produced by known enteric pathogens.

20 August 2019 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
TGTheresa B Gallagher
Theresa B Gallagher
GMGabriela Mellado-Sanchez
Gabriela Mellado-Sanchez
AJAna L Jorgensen
Ana L Jorgensen
SMStephen Moore
Stephen Moore
JNJames P Nataro
James P Nataro
LBLes Baillie
Les Baillie
Bacillus anthracis and Yersinia pestis are zoonotic bacteria capable of causing severe and sometimes fatal infections in animals and humans. Although considered as diseases of antiquity in industrialized countries due to animal and public health improvements, they remain endemic in vast regions of the world disproportionally affecting the poor. These pathogens also remain a serious threat if deployed in biological warfare. A single vaccine capable of stimulating rapid protection against both pathogens would be an extremely advantageous public health tool. We produced multiple-antigen fusion proteins (MaF1 and MaF2) containing protective regions from B. anthracis protective antigen (PA) and lethal factor (LF), and from Y. pestis V antigen (LcrV) and fraction 1 (F1) capsule. The MaF2 sequence was also expressed from a plasmid construct (pDNA-MaF2). Immunogenicity and protective efficacy were investigated in mice following homologous and heterologous prime-boost immunization. Antibody responses were determined by ELISA and anthrax toxin neutralization assay. Vaccine efficacy was determined against lethal challenge with either anthrax toxin or Y. pestis. Both constructs elicited LcrV and LF-specific serum IgG, and MaF2 elicited toxin-neutralizing antibodies. Immunizations with MaF2 conferred 100% and 88% protection against Y. pestis and anthrax toxin, respectively. In contrast, pDNA-MaF2 conferred only 63% protection against Y. pestis and no protection against anthrax toxin challenge. pDNA-MaF2-prime MaF2-boost induced 75% protection against Y. pestis and 25% protection against anthrax toxin. Protection was increased by the molecular adjuvant CARDif. In conclusion, MaF2 is a promising multi-antigen vaccine candidate against anthrax and plague that warrants further investigation. Anthrax and plague are ancient infectious diseases that continue to affect people living in poor, endemic regions and to threaten industrialized nations due to their potential use in biowarfare. Candidate vaccines need improvement to minimize non-desirable effects and increase their efficacy. The purpose of this work was to develop and evaluate a single subunit vaccine capable of conferring protection against Bacillus anthracis and Yersinia pestis. To this end, specific regions from their genome or key protective protein sequences from both microorganisms were combined to obtain either recombinant plasmids or recombinant proteins and tested as vaccine candidates in mice. The recombinant protein MaF2 induced specific antibody responses and afforded full and partial protection against Y. pestis and B. anthracis, respectively. Meanwhile, the DNA vaccine equivalent to MaF2 conferred only partial protection against Y. pestis, which increased when combined with an MaF2 protein boost. MaF2 emerged as a promising dual pathogen recombinant vaccine that warrants further investigation.

1 August 2017 in Pediatric Clinics of North America
Verified
Journal Article
Closed access
JNJames P. Nataro
James P. Nataro